1Temple R. Are surrogate markees adequate to assess cardiovascular drugs? JAMA1999;282:790-795.
2Drugs for hypertension. Med Left. 1999;41:23-28.
3The sixth report of the Joint National Committee on Prevention. Deteciton, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446
4Lasagna L. A plea for the "nat uralistic" study Of medicines. Eur J Clin Pharmacol 1974.7:153-154.
5The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascutar events In hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
6Armitage P. Sequential Medical Trials. 2nd ed. New York. NY: John Wiley &Sons Inc; 1975.
7Drug Evaluations. 6th ed. Chicago, Ⅲ: American Medical Association; 1986.
2Randall S. Stafford, MD, PhD Curt D. Furberg, MD, PhD Stan N. Finkelstein, MD 李呈亿（译）.1996—2002年临床试验结果对α-阻滞剂处方趋势的影响[J].美国医学会杂志（中文版）,2005,24(6):338-338.
